Spark Therapeutics, Inc. (NASDAQ:ONCE)‘s stock had its “buy” rating restated by analysts at Royal Bank Of Canada in a research note issued to investors on Wednesday.

A number of other brokerages have also recently issued reports on ONCE. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a report on Friday, August 25th. William Blair started coverage on shares of Spark Therapeutics in a report on Wednesday, June 28th. They issued an “outperform” rating for the company. Raymond James Financial, Inc. started coverage on shares of Spark Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $96.00 price objective for the company. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $60.00 to $100.00 in a report on Tuesday, August 8th. Finally, BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, August 26th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $90.47.

Spark Therapeutics (NASDAQ ONCE) traded down 1.35% on Wednesday, reaching $84.34. The company’s stock had a trading volume of 364,424 shares. The stock has a 50 day moving average price of $85.24 and a 200-day moving average price of $85.24. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $91.75. The company’s market capitalization is $2.64 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.04) earnings per share. Equities analysts predict that Spark Therapeutics will post ($7.59) earnings per share for the current fiscal year.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/25/royal-bank-of-canada-reiterates-buy-rating-for-spark-therapeutics-inc-once.html.

In other news, CEO Jeffrey D. Marrazzo sold 28,650 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total transaction of $2,292,286.50. Following the completion of the transaction, the chief executive officer now owns 258,650 shares of the company’s stock, valued at $20,694,586.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel Faga sold 6,000 shares of the company’s stock in a transaction dated Friday, October 20th. The shares were sold at an average price of $79.95, for a total transaction of $479,700.00. Following the transaction, the insider now directly owns 6,000 shares of the company’s stock, valued at approximately $479,700. The disclosure for this sale can be found here. Insiders have sold 1,121,837 shares of company stock valued at $94,360,267 in the last ninety days. 7.30% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in ONCE. Ameritas Investment Partners Inc. raised its position in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Spark Therapeutics during the second quarter valued at about $143,000. BNP Paribas Arbitrage SA raised its position in shares of Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 2,449 shares during the last quarter. Pacad Investment Ltd. raised its position in shares of Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 1,500 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new position in shares of Spark Therapeutics during the first quarter valued at about $227,000. 77.29% of the stock is owned by institutional investors and hedge funds.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.